Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia
(AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The
main question it aims to answer is:
• The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate
and GVHD incidence in high-risk AML patients after allo-HSCT.
Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.